SWP
RYTM icon

Stratos Wealth Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Stratos Wealth Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,264
Closed -$334K – 1445
2023
Q4 		$334K Sell
7,264
-8,262
-53% -$261K 0.01% 1031
2023
Q3 		$356K Sell
15,526
-13,058
-46% -$292K 0.01% 943
2023
Q2 		$471K Sell
28,584
-25,500
-47% -$460K 0.01% 786
2023
Q1 		$965K Sell
54,084
-19,236
-26% -$483K 0.03% 492
2022
Q4 		$2.14M Buy
73,320
+34,705
+90% +$892K 0.05% 337
2022
Q3 		$946K Buy
+38,615
New +$718K 0.03% 498

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Stratos Wealth Partners's RYTM Position: Q1 2024 in Review

Stratos Wealth Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2024, closing a stake of 7,264 shares — an estimated $334K sold.

Stratos Wealth Partners first reported a position in RYTM in Q3 2022 and held it in 6 quarters. The position peaked at $2.14M in Q4 2022. 167 funds tracked by Wall St. Rank hold RYTM as of Q1 2024.

  • Stratos Wealth Partners reported no remaining Rhythm Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Stratos Wealth Partners sold 7,264 Rhythm Pharmaceuticals shares in Q1 2024, an estimated $334K.
  • Stratos Wealth Partners first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Stratos Wealth Partners's Rhythm Pharmaceuticals position peaked at $2.14M in Q4 2022.
  • 167 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2024.

Based on Stratos Wealth Partners's 13F filing for Q1 2024, filed 16 Apr 2024.